Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

Evotec SE

JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULES JUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENT ON PROGRESS INTO COMMERCIAL MANUFACTURING AND EXERCISING THE S.POD OPTION THE PARTNERSHIP ASPIRES TO DISRUPT THE BIOSIMILARS MARKET WITH AFFORDABLE AND ACCESSIBLE HIGHEST-QUALITY MEDICINES FOR PATIENTS ACROSS THE GLOBE THE PARTNERSHIP IS FOUNDED ON JUST - EVOTEC BIOLOGICS' AI-DRIVEN, FULLY INTEGRATED TECH PLATFORM AND CONTINUOUS MANUFACTURING COMBINED WITH SANDOZ' LEADING BIOSIMILARS PIPELINE AND CAPABILITIES THE PARTNERSHIP INCLUDES AN OPTION FOR SANDOZ TO INLICENSE JUST - EVOTEC BIOLOGICS' FULL TECH STACK, INJECTED IN ITS FULLY-OWNED ‘S.POD' FACILITY TO EXPAND THE DISRUPTIVE DEVELOPMENT AND MANUFACTURING OF BIOSIMLARS IN THE LATTER PART OF THIS DECADE HAMBURG, GERMANY and SEATTLE, WA / ACCESSWIRE / May 9, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT), Prime Standard, ISIN: DE0005664809; (NASDAQ:EVO) and Sandoz AG, a division of Novartis (NASDAQ:NVS) today announced that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars. The partnership includes an option for the non-exclusive in-licensing of Just - Evotec Biologics' proprietary technology by Sandoz for building its fully-owned S.POD facility (in analogy to Just - Evotec Biologics' state-of-the-art J.POD facilities).

Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing

Boyd Gaming

Cummins

W.W. Grainger

PulteGroup

PulteGroup (PHM), Novartis (NVS), Boyd Gaming (BYD), Cummins (CMI) and W.W. Grainger (GWW) could be solid choices for your portfolio.

5 Dividend Growth Stocks to Buy for Safe Returns

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?

Novartis (NVS) Could Be a Great Choice

Ameriprise Financial

Blackrock Inc

CNH Industrial NV

Canadian Natural Resources

ConocoPhillips

General Mills

Genuine Parts

Hartford Financial Services Group

Hubbell

Infosys

KLA-Tencor

Kroger

Eli Lilly

Merck

NetEase

Novo Nordisk

Taiwan Semiconductor Manufacturing

United Microelectronics

The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%, not adjusted for greater than 2%+ dividends. The first May 2020 portfolio had +66.98% 2-year returns.

V&M Breakouts: Top Long-Term Growth And Dividend Stocks For May 2023

A strong product portfolio propelled Novartis' results during the first quarter. The company's market-doubling payout appears to be viable.

Is This Big Pharma Stock a Buy for Dividend Investors?

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for Cosentyx® (secukinumab) in adults with active moderate to severe hidradenitis suppurativa (HS).

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis will present new data from its oncology portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, including advancements in breast cancer, prostate cancer and lung cancer from more than 40 Novartis-sponsored and investigator-led trials. Primary results from the NATALEE trial evaluating Kisqali ® (ribociclib) plus endocrine therapy in patients with stage II and stage III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer at risk of cancer recurrence, regardless of nodal involvement, will be presented.

Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO

Basel, April 26, 2023 — Novartis today announced detailed results from the Phase III APPOINT-PNH trial of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with paroxysmal nocturnal hemoglobinuria (PNH)1. The trial met its primary endpoint and demonstrated clinically meaningful benefits across secondary endpoints1. These data were presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).

Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

Novartis (NVS) beats on earnings and sales in the first quarter, and raises its annual guidance on strong momentum.

Novartis (NVS) Tops on Q1 Earnings & Revenues, Ups View

Novartis AG (NVS) Q1 2023 Earnings Call Transcript.

Novartis AG (NVS) Q1 2023 Earnings Call Transcript

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Novartis (NVS) Reports Q1 Earnings: What Key Metrics Have to Say

Novartis stock jumped early Tuesday on a trio of drugs that helped drive its first-quarter earnings report to a beat-and-raise. The post Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise appeared first on Investor's Business Daily.

Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise

Novartis AG on Tuesday posted slightly higher net profit and sales for the first quarter of the year, beating analysts' expectations, and raised its guidance for the full year.

Novartis raises 2023 view, after posting higher profit and sales

Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD). Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core operating income +18% (cc, +11% USD). IM core margin 38.7%, +360 bps cc, driven by higher sales and productivity programs.

Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

Basel, April 20, 2023 — Novartis today announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta® (ofatumumab) had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta1. A separate analysis showed that treatment with Kesimpta for up to five years was well-tolerated, with no new or increased safety risks identified2. These data will be presented at the American Academy of Neurology (AAN) Annual Meeting held in Boston and virtually on April 22-27, 2023.

Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

Johnson & Johnson

Johnson & Johnson and Novartis both have robust product portfolios and pipelines. Each company pays a safe and market-topping dividend to shareholders.

2 Best Biotech Stocks to Buy for the Long Haul

BeiGene

Coherus BioSciences

Amicus Therapeutics

SPDR S&P Biotech ETF

China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.

The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.

Diageo

SAP SE

Sanofi

TotalEnergies SE

The consumer price index data showed this week that the rampant inflation that was in place a year ago is slowing, after peaking at 9.1% year-over-year in June of 2022.

5 European Dividend Aristocrats Offer Huge Growth and Income Potential With Diversification From the US

Amgen

Gilead Sciences

Pfizer

Walgreens

First-quarter earnings kick off in a big way on Friday with the major banks posting their results.

Why 7 of the Highest-Yielding ‘Strong Buy' Health Care Stocks Are the Absolute Best 2023 Buys

If you're looking to jump onboard a rocket, forget Jeff Bezos and Richard Branson. Shares of Swiss pharmaceutical giant Novartis AG (NYSE: NVS) catapulted 5.11% in the past week and 17.47% in the past month.

Novartis Shares Leap On Positive Clinical Trial Data

Novartis (NVS) receives a positive opinion from the CHMP for Entresto (sacubitril/valsartan) for a new indication in pediatric patients.

Novartis (NVS) Gets CHMP Positive Opinion for Entresto Approval

If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to

Novartis Entresto receives positive CHMP opinion for pediatric heart failure

Vertex Pharmaceuticals

Despite an unfavorable macro environment in 2022, some stocks did manage to churn out respectable gains last year. Novartis and Vertex Pharmaceuticals were two of last year's biggest winners within the large-cap space.

What Bear Market? These 2 Winning Stocks Are Still Worth Buying.

News for Novartis Stock (NVS)